Assessment of Blood Glucose Monitoring Devices With New Insight Features

LifeScan3 sites in 1 country267 target enrollmentOctober 1, 2016

ConditionsDiabetes Mellitus

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Diabetes Mellitus
Sponsor: LifeScan
Enrollment: 267
Locations: 3
Primary Endpoint: A1c change from baseline after 12 weeks
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To investigate whether novel insight features in new BGMs can improve glycemic control.

Registry

clinicaltrials.gov

Start Date

October 1, 2016

End Date

June 22, 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Factorial

Sex

All

Investigators

Sponsor

LifeScan

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

A1c change from baseline after 12 weeks

Time Frame: 12 weeks

A1c change from baseline after 12 weeks in subjects using BGMs with color range indicator and/or pattern messaging tools (i.e., OneTouch Verio® Flex and OneTouch Verio® combined) compared to subjects with either T1 or T2DM using their current BGM, i.e., without color range indicator and/or pattern messaging tools.